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Obesity and the Hypothalamus: Minireview
Novel Peptides for New Pathways
(thermogenesis), altered hormone (especially insulin)se-
cretion and action, and partitioning of energy stores
away from fat, all of which resist obesity. However, a
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second important role for leptin may be to signal starva-²Research Division
tion to the brain (Ahima et al., 1996). Falling leptin evokesJoslin Diabetes Center
a distinct set of adaptive responses, including dimin-³Department of Medicine
ished reproductive capacity and lower thyroid hormoneHarvard Medical School
levels, to conserve energy for survival. Both roles forBoston, Massachusetts 02215
leptin may exist, each at a different end of its biologic
dose±response curve.However,because starvation poses
a more immediate and frequent threat, the response to
The belief that the hypothalamus plays a role in the starvation might exceed in importance the avoidance of
regulation of energy homeostasis was originally based obesity from an evolutionary perspective.
upon the results of brain lesions. Disruption of the ven-
In any case, an understanding of obesity requires that
tromedial hypothalamus produced hyperphagic obesity,
the status of the leptin system in patients with obesity
while lesions of the lateral hypothalamus caused hypo- be explained. In the great majority of obese humans
phagia and weight loss, suggesting the existence of and in most rodent models, leptin levels are increased,
ventromedial ªsatietyº and lateral ªfeedingº centers. Al- indicating that most obesity is leptin resistant (Maffei et
though this framework is now recognized as simplistic, al., 1995). Two potential mechanisms for this resistance
it is the scaffold upon which an understanding of the have been explored. The first is a defect in the blood±
complex neurochemical system underlying regulation of brain barrier transport system for bringing leptin to CNS
appetite and energy expenditure has been built. Initially, sites of action. That such a defect exists is supported
physiologists examined the responses to injection of by the fact that high levels of serum leptin observed in
neurochemicals present in and around the hypothala- obesity are not paralleled by proportional rises in CSF
mus, using feeding, autonomic output, and hormonal leptin (Caro et al., 1996). The molecular basis for a trans-
measurements as a final readout. Such approaches de- port defect is unknown. A second site for leptin resis-
fined the effects of the neurotransmitters norepineph- tance involves defects in the sites of leptin action within
rine, dopamine, and serotonin, as well as neuropeptides the CNS. As a result, great attention has been focused
including neuropeptide Y (NPY), corticotropin-releasing upon the molecular targets of leptin action in the brain.
hormone (CRH), and galanin; and elements of a neural NPY: The Initial Target
wiring diagram began to take shape. Indeed, it appeared Initially, among several possible mediators of leptin ac-
possible, until several years ago, that the key molecular tion within the hypothalamus, NPY was the most com-
mediators in the brain were known, and only their mode pelling (reviewed in Erickson et al., 1996). Several prop-
of interaction remained to be defined. But the stability erties suggested that it might be an essential conduit
of body weight in the face of variable nutritional supplies for the leptin signal. Injection of NPY centrally evokes
suggested that additional molecular mediators and reg- virtually all of the features of leptin deficiency, including
ulatory pathways remained undiscovered. This suspi- hyperphagia, decreased brown adipose tissue (BAT)
cion has been validated by a number of recent discover- thermogenesis, and hyperinsulinemic insulin resistance.
ies, including one in this issue of Cell (Sakurai et al., Repetitive injection causes obesity. Its regulation fits as
1998). Through a combination of genetic and biochemi- well, since arcuate nucleus NPY is increased by starva-
cal approaches, novel molecular mediators and path- tion and in the leptin-deficient ob/ob mouse, and leptin
ways have been identified in the periphery and the brain, repletion restores this expression to normal. Thus, it
heralding an exciting new phase of discovery and ap- surprised most investigators when NPY knockout mice
plied research. lacked a feeding or obesity phenotype. Increased NPY
Leptin Is a Peripheral Signal Informing does contribute to the ob/ob phenotype, since ob/ob
the Brain of Energy Stores mice that also are NPY2/NPY2 are substantially less
The ob and db genes encode an adipocyte-derived hor- obese and have improvement (but not complete rever-
mone (e.g., leptin) and its receptor (Zhang et al., 1994; sal) of the ob/ob neuroendocrine phenotype (Erickson
Caro et al., 1996, and references therein). Leptin expres- et al., 1996). However, the obesity in these mice is severe
sion and function are essential for the avoidance of nonetheless, and NPY2/NPY2 mice respond normally
obesity, insulin-resistant diabetes, and infertility, an un- (or even excessively) to the satietyeffects of leptin.Thus,
derstanding that has profoundly changed the field of other targets of leptin must exist within the brain for
nutritional physiology. Although the consequences of bringing about the responses to both low and high leptin
the absence of leptin signaling are clear, determining levels.
the normal physiological role for leptin required further The agouti, POMC, Melanocortin Connection
experimentation. One model is that circulating leptin In parallel with progress on leptin and NPY, a second
levels rise with nascent obesity, engaging receptors in front has developed rapidly in the realm of leptin targets
the hypothalamus, where actions are initiated that limit in the hypothalamus. The initial observation came from
food intake and alter autonomic output (Zhang et al., the lethal yellow (Ay/a) mouse, an autosomal dominant
obesity model. Obesity in these mice is accompanied1994). The latter stimulates increased heat production
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expresses NPY), approximately 30% of the POMC neu-
rons express the mRNA for the leptin receptor long form,
and arcuate POMC mRNA expression is regulated posi-
tively by leptin (Thornton et al., 1997). Thus, one can
envision a loop in which rising leptin (with obesity) drives
increased arcuate POMC expression, which then proj-
ects a-MSH containing axons to MC4R-expressing cell
bodies elsewhere in the hypothalamus, causing de-
creased food intake.
But the MC4 receptor pathway is not restricted to a
single agonistic ligand, as a newly discovered neuropep-
tide acts as an antagonist on this same receptor. Agouti-
related peptide (AGRP), also named agouti-related tran-
script (ART), is a homolog of agouti (Ollmann et al., 1997,
and references therein) whose expression is largely re-
stricted to the arcuate nucleus, where it is markedly
increased in leptin deficient ob/ob mice. AGRP antago-Figure 1. A Model of the Pathways of Leptin Action in the Hypo-
thalamus nizes a-MSH at the MC4-R (but not the MC1-R), and its
Through direct actions on cell bodies in the arcuate nucleus (ARC), forced ectopic expression in transgenic mice produces
leptin positively regulates POMC (a-MSH) and negatively regulates obesity closely resembling that of the MC4-R knockout
NPY and AGRP. a-MSH neurons project to MC4 receptor-express- mouse (Ollmann et al., 1997). Therefore, AGRP almost
ing neuronsof as-yet-uncertain chemical identity. AGRP-expressing
certainly acts as an antagonist at the MC4-R, as oneneurons antagonize the a-MSH signal on these neurons. Directly or
member of an apparent yin±yang pair with a-MSH. Theindirectly, this signal influences neurons in the lateral hypothalamus
output from the feeding inhibitory MC4 receptor may be(LHA) that then influence hunger/satiety by mechanisms that may
include long cortical projections involving MCH neurons. NPY proj- determined by the ratio of agonist (MSH) and antagonist
ects to the paraventricular nucleus (PVN), which contains neurons (AGRP) at MC4 receptor neurons.
expressing CRH and TRH (and other neuropeptides). The PVN influ- Does the MC4 receptor lay downstream of the path-
ences anterior and posterior pituitary functions. The PVN also di-
way by which leptin induces some or all of its effects?rectly innervates autonomic preganglionic neurons, both sympa-
Since MC4 receptor blockade or knockout producesthetic and parasympathetic. The dorsomedial hypothalmus (DMH)
obesity, but not reproductive failure or hypercortisolismhas neurons that are responsive to leptin and project to the PVN.
as seen in leptin-deficient mice, it appears that MC4
receptor signaling is not required for the neuroendocrine
by increased linear growth and altered hair pigmenta- effects of leptin deficiency. Is this pathway required for
tion. The disorder is caused by ectopic and unregulated the satiety effects of elevated leptin? A downstream
expression of agouti, a protein normally restricted to hair role for MC4 receptors in the satiety action of leptin is
follicles where it affects pigmentation by antagonizing supported by two lines of evidence. First, Ay mice with
melanocyte stimulating hormone (a-MSH). A break- MC4 receptor blockade develop obesity despite marked
through came with the demonstration that agouti antag- hyperleptinemia, and leptin administered peripherally or
onizes several members of the melanocortin receptor into the CSF has markedly reduced effect (Halaas et al.,
family (Lu et al., 1994), including theMC1 receptor in hair 1997). Second, pretreatment of rodents with an MC4
follicles (explaining the coat color) and MC4 receptors, receptor antagonist acutely blocks the satiety-inducing
which are largely restricted to thebrain. This observation action of leptin (Seeley et al., 1997). However, this view
suggested that melanocortin receptor blockade in the of the leptin-melanocortin axis has been challenged by
brain could produce obesity, and has been followed by results of a genetic cross between ob/ob and Ay/a mice.
observations defining a system for metabolic regulation In these experiments, the Ay and ob/ob lesions were
by two opposing ligands, one an agonist and the other demonstrated to have additive effects on weight gain
an antagonist at the MC4 receptor (Figure 1). and serum insulin. These mice respond normally to ex-
Two results placed the MC4 receptor at a pivotal posi- ogenous leptin, suggesting that the leptin resistance of
tion in the central pathways for energy homeostasis. Ay/a mice requires, or is in some way a consequence of,
Targeted deletion of the MC4 receptor produced a syn- the chronic leptin excess (Boston et al., 1997). Potential
drome of obesity (Huszar et al., 1997) similar to that of mechanisms might include down-regulation of leptin re-
Ay mice, absent the pigmentary defect that required ceptor or downstream signaling, or induction of antago-
deregulated expression of agouti in skin acting on MC1 nists by chronic leptin exposure. Clearly, the MC4 recep-
receptors. Additionally, the observations of decreased tor is likely to mediate some of leptin's actions, but
feeding after central administration of agonists (e.g., additional work will be required to define precisely what
a-MSH) and the increased feeding after administration these are.
of a synthetic receptor antagonist (Fan et al., 1997) pro- From the Mediobasal to the Lateral Hypothalamus
vide pharmacological evidence for the role of the MC4 Heretofore, the molecular focus has been on the medio-
receptor. What is the endogenous ligand for this re- basal hypothalamus, where the signaling form of the
ceptor? Recent studies have produced a number of leptin receptor and neuronal cell bodies expressing
surprises. a-MSH, produced from proopiomelanocortin NPY, POMC, and AGRP reside, all apparently under
(POMC) precursors, appears to fit the role of agonist to leptin control. But how do the signals from these sites
impact the neural underpinning of hunger and satiety,decrease feeding. In the arcuate nucleus (which also
Minireview
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and by what route does the lateral hypothalamus play Hypocretin
The secondnovel factor localized to the lateral hypothal-a role? Although the distance separating the arcuate
amus is hypocretin, which is exclusively expressed innucleus and lateral hypothalamus is but a few millime-
the lateral hypothalamus (de Lecca et al., 1998). Hypo-ters, complex neural circuitry is likely involved, as infor-
cretin was discovered through direction tag PCR sub-mation from leptin signaling is integrated with numerous
traction, the goal of which was to identify mRNAs specif-other inputs relevant to nutritional homeostasis, includ-
ically expressed in hypothalamus. Hypocretin mRNAing circadian signals and inputs from higher centers.
encodes two peptides that have homology to the gutOne potential link between the mediobasal hypothala-
hormone secretin, and neurons encoding hypocretin aremus and the lateral hypothalamus may involve melano-
located in an area that overlaps the distribution of MCH-cortin 4 receptors. These receptors are expressed in
containing neurons. Projections of these neurons arecells of the lateral hypothalamus (Mountjoy et al., 1994),
complex and extend into the arcuate nucleus, the septalbut the chemical identity of these neurons is unknown.
nucleii and the basal forebrain, and the preoptic area.These neurons may provide an important link between
The signaling role of the hypocretins and whether theythe early steps of leptin action and the higher functions
have any role in body weight regulation remain unde-that underlie food-seeking behavior, since cells within
fined.the lateral hypothalamus (such as MCH neurons, see
Orexinsbelow) directly innervate higher cortical centers. Leptin-
Finally, discovery of the two orexins and their receptorsresponsive cells in the dorsomedial hypothalamus may
is reported in this issue of Cell (Sakurai et al., 1998). Theplay a major role in transducing leptin's effects on auto-
effort that led to this discovery is a technical tour denomic output (Elmquist et al., 1998).
force. Yanigasawa and colleagues sought ligands thatNew Mediators in the Lateral Hypothalamus
bound to orphan G protein±coupled receptors. UsingThe molecular mechanism for signaling from lateral hy-
cell lines expressing 50 of these, they searched brainpothalamus to higher centers that regulate hunger and
extracts for activation of calcium currents and suc-satiety has been obscure, but once again, genetic ap-
ceeded in purifying and cloning cDNAs encoding twoproaches have begun to clarify the chemical anatomy.
related peptides, orexins A and B, produced from aBy three distinct genetic approaches, five novel lateral
single protein precursor by proteolytic processing. Thehypothalamic neuropeptides that may play important
mRNA expressing the orexins is expressed in an ex-roles in energy balanceand obesity have been identified.
tremely limited distribution within the lateral hypothala-Melanin-Concentrating Hormone (MCH)
mus, with some expression within the testes. Remark-The first new actor was melanin-concentrating hormone
ably, orexin expression increases with starvation, and(MCH) (Nahon, 1994, and references therein). Initially
central administration induces hyperphagia. Thus, quitediscovered in chub salmon pituitaries, salmon MCH cir-
rapidly, the number of peptides selectively expressedculates and regulates skin color by acting on melano-
in the lateral hypothalamus has increased from none tosomes within pigmented skincells. MCH lightens skin by
five, and the number regulated by nutrition and capableinducing aggregation of melanosomes. a-MSH induces
of inducing hyperphagia has gone from none to three.skin darkening in this system, by inducing dispersion of
It will be critical to determine whether MCH, orexins,melanosomes. Thus, MCH and a-MSH are functional,
and hypocretins are expressed in the same cells, andthough not pharmacological antagonists in the fish scale
to map the projections of these cells throughout thesystem.
brain. Potential functional interactions between theseThe presence of MCH in mammalian hypothalamus
neuropeptides are also of great interest.was described in the mid-1980s, confined to a group of
New Directions
magnocellular neurons in the lateral hypothalamus and
Having identified an array of new neurochemicals that
zona incerta. MCH neurons project to the nucleus of the
regulate appetite and energy homeostasis, much still
solitary tract and theparabrachial nucleus, but arehighly
remains tobe done. First, there is little reason to suspect
unusual in also having diffuse monosynaptic projections that the last of the important actors has been discov-
to the medial prefrontal cortex, leading to suggestions ered, and so fishing expeditions will be trolling hypothal-
that MCH plays a role in complex integrative behaviors. amic waters in search of more big trophy catches. New
PCR-based differential display was employed to iden- molecules in the pathway, such as MCH, orexins, and
tify mRNA's that were expressed differentially in the hypocretins will be deleted and overexpressed, and ge-
hypothalamus of ob/ob mice compared to littermate netic models will be combined to produce models of
controls, and MCH came out of this screen (Qu et al., gene interactions in vivo. A role of these genes in human
1996). Overexpression of MCH mRNA was seen in ob/ obesity will also be sought. Since monogenic human
ob mice; fasting increased expression both in control obesities are likely to be uncommon, it will be necessary
and ob/ob animals. Intracerebroventricular administra- to probe interactions between the central pathways that
tion to rats stimulated feeding. It is of interest that MCH respond to leptin and other signals involved in energy
and a-MSH have opposing actions in rat brain, as they homeostasis. For example, what are the adaptations to
do in fish scales. This opposition is in models of auditory knockout or overexpression of individual neuropeptides
gating, grooming, and most recently feeding. However, and receptors, and how do these potential adaptations
unlike a-MSH and AGRP, which antagonize each other interact with genetic background and environmental
by acting on the same receptor, MCH has no affinity for conditions such as diet and stress.
known melanocortin receptors and acts via an as-yet- The foregoing reminds us that, for humans at least,
decisions to eat or not (or more precisely what to eatunidentified receptor.
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and when to stop) are highly complex, residing at the
fuzzy interface between free will and physiology. We
eat for many reasons, including those that are hedonic,
those that emerge from psychic conflicts, and those
that relate to basic survival. Our new knowledge of the
chemical anatomy of the lateral hypothalamus is a long
way from reducing these complex issues to simple syn-
aptic equations. On the other hand, since massive obe-
sity in humans may result from defective signaling by a
single receptor (e.g., the leptin receptor) (Montague et
al., 1997), we are reminded that the genetic roots of
hunger and satiety in humans run deep. The continued
pursuit of these factors will be productive for years to
come.
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